ArticleJournal of chemical information and modeling2026
Improving AlphaFold2 Performance in Virtual Screens Targeting GPCRs by Enhancing Binding-Site Conformational Sampling.
Article in Journal of chemical information and modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Benchmarking AI Protein Structure Predictors Reveals a Persistent Bias in Multi-State Proteins.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial intelligence has transformed protein structure prediction, with AlphaFold2 (AF2) generating models with near-experimental accuracy. However, as AF2 was trained to generate a single structural model, this method does not capture the conformational flexibility of proteins, limiting its utility for structure-based drug design. Here, we explore strategies to generate diverse ensembles of binding-site models suitable for structure-based virtual screening against G protein-coupled receptors (GPCRs), a major class of drug targets. Our AFsample2T approach uses multiple sequence alignment column masking in the receptor binding site to reduce coevolutionary signals, leading to greater structural heterogeneity in the generated models. We demonstrate that ensembles of AFsample2T models capture multiple relevant binding-site conformations and reproduce experimentally observed conformational variability. Evaluation of AF2-based models in structure-based virtual screening using docking of actives and decoys shows that considering ensembles of diverse binding-site models substantially improves ligand enrichment. Our results provide guidelines for using AF2-based models in structure-based ligand discovery for GPCRs, and the AFsample2T approach can readily be applied to other protein classes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.